Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
4 min read
SpliSense has successfully concluded the Phase 1 clinical trial of SPL84, an RNA-based therapy aimed at treating Cystic Fibrosis
11 September 2023
SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.
Drug Insights
4 min read
A Comprehensive Review of Cinacalcet hydrochloride's R&D Innovations
11 September 2023
This article summarized the latest R&D progress of Cinacalcet hydrochloride, the Mechanism of Action for Cinacalcet hydrochloride, and the drug target R&D trends for Cinacalcet hydrochloride.
Latest Hotspot
3 min read
Verismo Therapeutics provides SynKIR-110 treatment for the first advanced cancer patient in clinical trials
11 September 2023
Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.
Drug Insights
4 min read
Pharmaceutical Insights: Vardenafil hydrochloride's R&D Progress
11 September 2023
This article summarized the latest R&D progress of Vardenafil hydrochloride, the Mechanism of Action for Vardenafil hydrochloride, and the drug target R&D trends for Vardenafil hydrochloride.
Valuable Targets
6 min read
Latest Developments in the Research and Development of BET inhibitor
11 September 2023
BET (Bromodomain and Extra-Terminal) proteins play a crucial role in the regulation of gene expression in the human body.
Latest Hotspot
4 min read
Viking Therapeutics has launched the Phase 2 VENTURE study of the combined GLP-1/GIP receptor agonist VK2735 for obese patients
11 September 2023
Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.
Drug Insights
4 min read
Exploring Valrubicin's Revolutionary R&D Successes and its Mechanism of Action
11 September 2023
This article summarized the latest R&D progress of Valrubicin, the Mechanism of Action for Valrubicin, and the drug target R&D trends for Valrubicin.
Latest Hotspot
3 min read
FDA authorizes initiation of IND for ATA-100, a Genetic Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
11 September 2023
Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.
Valuable Targets
6 min read
Bcl-2 inhibitors show promise for the treatment of various hematological malignancies
11 September 2023
Bcl-2 inhibitors can be used alone to kill cancer cells or can be used in combination with other drugs to increase the sensitivity of cancer cells to drugs.
Latest Hotspot
4 min read
VBI vaccine release brii-179 (vbi-2601) combined with PEG-IFN α Results of the second phase study on the treatment of chronic hepatitis B
11 September 2023
VBI Vaccines Inc. publicized that its strategic HBV collaborator, Brii Biosciences announced preliminary group-level unmasked 36-week data from a mid-term examination of a randomly assigned, placebo-controlled, and double-concealed Phase 2 investigation of BRII-179 (VBI-2601).
Drug Insights
3 min read
Decoding Naxitamab: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
11 September 2023
This article summarized the latest R&D progress of Naxitamab, the Mechanism of Action for Naxitamab, and the drug target R&D trends for Naxitamab.
Latest Hotspot
4 min read
The combination regimen of amitabacizumab demonstrated significant effects in the Phase 3 MARIPSA-2 trial
11 September 2023
Johnson's Janssen Pharmaceutical Companies have disclosed encouraging preliminary findings from the tri-modality Phase 3 MARIPOSA-2 trial.